Axicabtagene Ciloleucel Approaches EU Approval for DLBCL, PMBCL
Pharma & biotech2018-06-29
33 Views
The European Medicines Agency’s CHMP has recommended approval of axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.
Source: OncLive
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
The Best Web Architectures for Your Business App
CompTIA Security+: Vendor-Neutral Badge with Limitless Opportunities. How to Earn It with Practice Tests?
